FMT shows promise in restoring gut barrier function, immunity in cirrhosis

Fecal microbiota transplantation improved gut barrier function, mucosal immunity and ammonia metabolism in patients with cirrhosis, which could reduce hepatic encephalopathy and other infections, according to data from the PROFIT trial.“Patients with cirrhosis have enteric dysbiosis,” Lindsey A. Edwards, BSC, MSc, PhD, research director of fecal microbiota transplant program at the Institute of Liver Studies at King’s College London, said during EASL Congress. “This means they lose beneficial [gut] species and they have enhanced pathogens. These cause damage and youRead More